Leerink Partnrs Lifts Earnings Estimates for AnaptysBio

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for AnaptysBio in a research report issued on Monday, November 10th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of ($1.08) for the year, up from their previous estimate of ($1.11). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.07 EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at $6.49 EPS and FY2029 earnings at $4.52 EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright lowered their target price on AnaptysBio from $59.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Guggenheim increased their price objective on shares of AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday. Wells Fargo & Company upped their price objective on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.40.

AnaptysBio Stock Performance

AnaptysBio stock traded up $0.49 during midday trading on Thursday, reaching $33.58. 59,513 shares of the company’s stock were exchanged, compared to its average volume of 704,066. The stock’s 50-day simple moving average is $29.56 and its 200 day simple moving average is $24.97. The firm has a market cap of $929.69 million, a price-to-earnings ratio of -11.91 and a beta of 0.16. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.96.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The firm had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently bought and sold shares of ANAB. First Light Asset Management LLC boosted its holdings in AnaptysBio by 433.3% in the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares during the period. Palo Alto Investors LP increased its holdings in shares of AnaptysBio by 20.9% in the first quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock worth $18,975,000 after buying an additional 176,742 shares during the period. Assenagon Asset Management S.A. boosted its holdings in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after acquiring an additional 822,975 shares during the period. Woodline Partners LP grew its position in AnaptysBio by 63.1% during the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after acquiring an additional 305,950 shares during the last quarter. Finally, 683 Capital Management LLC increased its stake in AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.